Advances in the development of personalized neoantigen-based therapeutic cancer vaccines von Blass, Eryn, Ott, Patrick A.

Volltext

Towards personalized, tumour-specific, therapeutic vaccines for cancer von Hu, Zhuting, Ott, Patrick A., Wu, Catherine J.

Volltext

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients von OTT, Patrick A, HODI, F. Stephen, ROBERT, Caroline

Volltext

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial von Sharma, Padmanee, Prof, Callahan, Margaret K, MD, Bono, Petri, MD, Kim, Joseph, MD, Spiliopoulou, Pavlina, MD, Calvo, Emiliano, MD, Pillai, Rathi N, MD, Ott, Patrick A, MD, de Braud, Filippo, Prof, Morse, Michael, Prof, Le, Dung T, MD, Jaeger, Dirk, MD, Chan, Emily, MD, Harbison, Chris, PhD, Lin, Chen-Sheng, PhD, Tschaika, Marina, MD, Azrilevich, Alex, PharmD, Rosenberg, Jonathan E, MD

Volltext

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study von Ott, Patrick A, Elez, Elena, Hiret, Sandrine, Kim, Dong-Wan, Morosky, Anne, Saraf, Sanatan, Piperdi, Bilal, Mehnert, Janice M

Volltext

Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect von Ott, Patrick A.

Volltext

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy von Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K, Joe, Andrew, Cheng, Jonathan, Webber, Andrea L, Ibrahim, Nageatte, Plimack, Elizabeth R, Ott, Patrick A, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K, Tomassini, Joanne E, Loboda, Andrey, Kaufman, David

Volltext

Talimogene Laherparepvec for the Treatment of Advanced Melanoma von Ott, Patrick A, Hodi, F Stephen

Volltext

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study von Mehnert, Janice M., Bergsland, Emily, O’Neil, Bert H., Santoro, Armando, Schellens, Jan H. M., Cohen, Roger B., Doi, Toshihiko, Ott, Patrick A., Pishvaian, Michael J., Puzanov, Igor, Aung, Kyaw L., Hsu, Chiun, Le Tourneau, Christophe, Hollebecque, Antoine, Élez, Elena, Tamura, Kenji, Gould, Marlena, Yang, Ping, Stein, Karen, Piha‐Paul, Sarina A.

Volltext

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 von Varga, Andrea, Piha-Paul, Sarina, Ott, Patrick A., Mehnert, Janice M., Berton-Rigaud, Dominique, Morosky, Anne, Yang, Ping, Ruman, Jane, Matei, Daniela

Volltext

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course von Nishino, Mizuki, Ramaiya, Nikhil H, Awad, Mark M, Sholl, Lynette M, Maattala, Jennifer A, Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A, Armand, Philippe F, Hodi, F Stephen

Volltext

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial von Frenel, Jean-Sebastien, Le Tourneau, Christophe, O'Neil, Bert, Ott, Patrick A, Piha-Paul, Sarina A, Gomez-Roca, Carlos, van Brummelen, Emilie M J, Rugo, Hope S, Thomas, Shari, Saraf, Sanatan, Rangwala, Reshma, Varga, Andrea

Volltext

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma von Luke, Jason J, Ott, Patrick A

Volltext

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study von Ott, Patrick A, Bang, Yung-Jue, Berton-Rigaud, Dominique, Elez, Elena, Pishvaian, Michael J, Rugo, Hope S, Puzanov, Igor, Mehnert, Janice M, Aung, Kyaw L, Lopez, Juanita, Carrigan, Marion, Saraf, Sanatan, Chen, Mei, Soria, Jean-Charles

Volltext

PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma? von Blass, Eryn, Ott, Patrick A

Volltext

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 tri... von Hodi, F Stephen, Dr, Chesney, Jason, Prof, Pavlick, Anna C, MD, Robert, Caroline, Prof, Grossmann, Kenneth F, MD, McDermott, David F, MD, Linette, Gerald P, MD, Meyer, Nicolas, Prof, Giguere, Jeffrey K, MD, Agarwala, Sanjiv S, Prof, Shaheen, Montaser, MD, Ernstoff, Marc S, Prof, Minor, David R, MD, Salama, April K, MD, Taylor, Matthew H, MD, Ott, Patrick A, MD, Horak, Christine, PhD, Gagnier, Paul, MD, Jiang, Joel, PhD, Wolchok, Jedd D, Prof, Postow, Michael A, MD

Volltext

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer von Janjigian, Yelena Y, Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W, Ascierto, Paolo A, Sharma, Padmanee, Ott, Patrick A, Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T, Dorange, Cecile, Tschaika, Marina, Le, Dung T

Volltext

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort von Ready, Neal E., Ott, Patrick A., Hellmann, Matthew D., Zugazagoitia, Jon, Hann, Christine L., de Braud, Filippo, Antonia, Scott J., Ascierto, Paolo A., Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D. Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K., Spigel, David R.

Volltext

Directing Traffic: How to Effectively Drive T Cells into Tumors von Anandappa, Annabelle J, Wu, Catherine J, Ott, Patrick A

Volltext

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients von De Velasco, Guillermo, Je, Youjin, Bossé, Dominick, Awad, Mark M, Ott, Patrick A, Moreira, Raphael B, Schutz, Fabio, Bellmunt, Joaquim, Sonpavde, Guru P, Hodi, F Stephen, Choueiri, Toni K

Volltext